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Abstract
Lung cancer is the leading cause of cancer deaths world-wide. Recent advances in cancer biology
have led to the identification of new targets in neoplastic cells and the development of novel
targeted therapies. At this time, two targeted agents are approved by the FDA in advanced non-
small cell lung cancer (NSCLC): the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) erlotinib, and the anitangiogenic bevacizumab. A third agent, cetuximab, which was
recently shown to enhance survival when used with cisplatin and vinorelbine as first line therapy
for advanced NSCLC, will likely be approved by regulatory agencies. With more than 500
molecularly targeted agents under development, the prospects of identifying novel therapies that
benefit individual patients with lung cancer are bright.
Introduction
Lung cancer is the leading cause of cancer deaths for both
men and women. It accounts for an estimated 15% of all
new cancer cases diagnosed in the United States in 2008,
and is responsible for an estimated 29% of all cancer
deaths [1]. World-wide, the impact of lung cancer is enor-
mous, with 1.35 million cases and approximately 1.18
million deaths [2]. Non-small cell lung cancer (NSCLC),
which accounts for approximately 85% of all cases of lung
cancer, will cause an estimated 161,840 deaths in the
United States in 2008 [1]. Approximately 70% of patients
with NSCLC have inoperable locally advanced tumors or
metastatic disease at the time of diagnosis.
In the past two decades the median survival has improved
disappointingly little. In 1975 the 5-year relative survival
rate for all patients with lung cancer was 13%. In the
period from 1996 to 2003 the 5-year survival rate
increased to only 16% despite the incorporation of mod-
ern chemotherapy regimens and great advances in sup-
portive care [1]. Yet, the future for lung cancer is bright.
Chemotherapy improves survival when administered
postoperatively to patients with stage II and IIIA NSCLC
and when administered with radiation in patients with
unresectable stage III disease. The median survival for
patients with advanced disease in particular has increased
with use of improved chemotherapy, targeted therapies
and better supportive care. New insights into the patho-
genesis of lung cancer are helping to identify more targets
for novel therapies. Some of these exciting new agents will
be highlighted here.
Tyrosine Kinase Receptor (RTK) Mechanisms of Disease
Where normal cells require growth factors in their culture
medium in order to grow, cancer cells have a greatly
reduced dependence on growth factors for their growth
and survival. The reason for this inconsistency was uncov-
ered in 1984 when the sequence of the EGF receptor was
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identified and found to be similar to the erbB oncogene.
This oncogene was originally discovered in the genome of
the avian erythroblastosis virus, a transforming retrovirus
that rapidly induces leukemia in red blood cell precursors
(erythroleukemia) [3]. The oncoprotein specified by the
erbB oncogene was found to lack sequences present in the
N-terminus of the EGF receptor allowing for constitutive
growth and survival signals independent of growth factors
that are typically required to activate the normally func-
tioning EGF receptor. Thus, tumor cells, like leukemic
cells were not dependent on growth signals for survival.
The EGF receptor is only one of a large number of simi-
larly structured receptors that contain intracellular tyro-
sine kinase domains. The unique extracellular domain of
these tyrosine kinase receptors (RTKs) is what permits
them to be classified into distinct families (Figure 1).
When activated by binding specific ligands, RTKs dimerize
and phosphorylate the intracellular tyrosine kinase por-
tions of the protein. The activated receptor molecule then
may phosphorylate and trigger a diverse array of down-
stream signaling pathways, including the Ras-Raf-MEK
(mitogen-activated and extracellular-signal regulated
kinase kinase), ERK1 and ERK2 (extracellular-signal regu-
lated kinase 1 and 2) pathway leading to cell growth, the
mTOR (mammalian target of rapamycin) pathway lead-
ing to protein synthesis, and the PI3K-AKT (phosphatidyl-
nositol-2 kinase Akt) pathway sustaining cell survival
(Figure 2).
In cancer cells, abnormal cell signaling through the RTK
pathways is initiated by various mechanisms including:
increased production of growth factors, overexpression of
growth factor receptors on the cell membrane, and muta-
tions in the receptor or downstream signaling enzymes.
The end results are: proliferation, block of apoptosis, ang-
iogenesis, and metastasis [4-6].
Epidermal Growth Factor Receptor (EGFR)
There are 4 members of the EGFR family: EGFR, HER2,
HER3, and HER4. Their interactions with extracellular lig-
ands as well as downstream signaling pathways are sum-
marized in Figure 3. After a ligand binds to a single-chain
EGFR, the receptor forms a dimer that leads to intracellu-
lar phosphorylation and exposure of the catalytic cleft,
activating a diverse array of downstream signaling path-
ways.
There are two classes of EGFR antagonists that are used in
clinical practice for non-small cell lung cancer at this time:
anti-EGFR monoclonal antibody (cetuximab), and small-
molecule EGFR tyrosine kinase inhibitors (TKIs) (gefit-
inib and erlotinib).
First Generation Small Molecule TKIs: Gefitinib and 
Erlotinib
Gefitinib was the first anti-EGFR agent shown to have
clinical activity. In two phase II trials gefitinib was evalu-
Tyrosine Kinase Receptor (RTK) families Figure 1
Tyrosine Kinase Receptor (RTK) families. Adapted by 
permission from Macmillan Publishers Ltd: The Biology of 
Cancer, Garland Science, 2007.
EGFR signaling pathways Figure 2
EGFR signaling pathways. Two important cell-survival 
pathways that operate downstream of activated ErbB trans-
membrane receptor tyrosine kinases (represented by pairs of 
yellow, and yellow and blue receptors to represent homo- 
and hetero-dimers, respectively), along with some of the key 
constituent signaling molecules are shown. The Ras-Raf-
MEK-ERK pathway is shown on the left, and the phosphati-
dylinositol 3-kinase (PI3K)-AKT pathway is shown on the 
right. Key points along the pathway where targeted inhibition 
seems to exert a blockade are indicated by red circles, show-
ing the relevant proteins they target. ERK, extracellular sig-
nal-regulated kinase; GRB2, growth factor receptor-bound 
protein 2; mTOR, mammalian target of rapamycin; SOS, son 
of sevenless. Used with permission from: Nature Reviews 
2007 Sharma et al. Pg 177.Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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ated in patients with advanced non-small cell lung cancer,
stage III or IV, who were treated with one or more regi-
mens containing cisplatin or carboplatin and docetaxel
and had progressed. In both studies symptom improve-
ment rates were around 40%, with 1-year overall survival
rates ranging between 25–35% [7,8]. These results, as well
as the observation that a few patients had dramatic
responses, resulted in approval for gefitinib, prior to a
phase III study, as second-line therapy.
The subsequent phase III trial comparing gefitinib with
placebo as second line therapy failed to show an improve-
ment in survival. Neither median survival nor the rate of
survival at 1 year differed significantly between the two
study arms [9]. Pre-planned subgroup analysis showed a
significant survival benefit for patients of Asian heritage,
and those who never smoked. Based on these results the
FDA restricted the use of gefitinib to patients participating
in a clinical trial or continuing to benefit from treatment
already initiated.
Recently, gefitinib was evaluated in a randomized phase II
trial that compared gefitinb with vinorelbine in chemo-
therapy naïve elderly patients (age > 70 years) with
advanced NSCLC. Patients were assigned to gefitinb 250
mg/day orally or vinorelbine 30 mg/m2 infusion on days
1 and 8 of a 21-day cycle. With nearly one hundred
patients in each study arm, there was no statistical differ-
ence between gefitinb and vinorelbine in efficacy, but
there was better tolerability with gefitinib (treatment-
related grade 3 to 5 adverse events with gefitinib were
12.8% vs. 41.7% for vinorlebine) [10].
A second small-molecule EGFR tyrosine kinase inhibitor,
erlotinib, was also found to have anti-tumor activity in
phase II trials [11-13], but, unlike gefitinib, demonstrated
improved survival in a placebo controlled phase III study.
In the BR.21 trial, treatment with erlotonib was associated
with a 2-month increase in survival in previously treated
patients with NSCLC. The median overall survival for
patients on the placebo group was 4.7 months compared
with 6.7 months for the erlotonib group (hazard ratio
[HR], 0.70; P < 0.001) [14]. The majority of patients in
both arms had a performance status (PS) of 0–1 (68.3%
in the placebo group and 65.6% in the erlotinib group). A
significant number of patients had a PS of 2, 23% in the
placebo group and 25.8% in the erlotinib group. Only
8.6% of patients in both groups had a PS of 3. 50% of
patients in erlotinib group as well as the placebo group
had previously received one chemotherapy regimen, and
half received two or more regimens. In the BR.21 trial the
response was higher among Asians, women, patients with
adenocarcinoma, and lifetime nonsmokers. Also, the
response rate was higher when 10 percent or more of
tumor cells expressed EGFR. The presence of EGFR gene
mutations was not predictive of a survival benefit from
erlotinib. Based on these results, erlotinib was approved
for second and third line therapy in NSCLC. The improve-
ment in overall survival seen with erlotinib in the BR.21
trial was comparable to the benefit from docetaxel in the
second-line setting [15]. In a separate analysis of BR.21
patients, erlotinib was also shown to improve tumor-
related symptoms, physical function (31% erlotinib vs.
19% placebo, P = 0.01), and global quality of life (35% vs.
26%, P < 0.0001) [16].
Four phase III, double-blind, placebo-controlled, rand-
omized clinical trials evaluated erlotonib or gefitinib with
chemotherapy as first-line treatment for non-small-cell
EGFR signal transduction pathways Figure 3
EGFR signal transduction pathways. Three steps can be 
schematically defined in the activation of EGFR-dependent 
intracellular signaling. First, the binding of a receptor-specific 
ligand occurs in the extracellular portion of the EGFR or of 
one of the EGFR-related receptors (HER2, HER3, or HER4). 
Second, the formation of a functionally active EGFR-EGFR 
dimer (homodimer) or an EGFR-HER2, EGFR-HER3, or 
EGFR-HER4 dimer (heterodimer) causes the ATP-dependent 
phosphorylation of specific tyrosine residues in the EGFR 
intracellular domain. Third, this phosphorylation triggers a 
complex program of intracellular signals to the cytoplasm 
and then to the nucleus. The two major intracellular path-
ways activated by EGFR are the RAS-RAF-MEK-MAPK path-
way, which controls gene transcription, cell-cycle 
progression from the G1 phase to the S phase, and cell pro-
liferation, and the PI3K-Akt pathway, which activates a cas-
cade of anti-apoptotic and prosurvival signals. bFGF, basic 
fibroblast growth factor, HB-EGF, heparin-binding EGF, 
MAPK, mitogen-activated protein kinase, PI3K, phosphatidyli-
nositol 3,4,5-kinase, TGFa transforming growth factor alpha, 
and VEGF, vascular endothelial growth factor. Used with per-
mission from: NEJM 2008 Ciardiello et al.).Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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lung cancer [17-20] (Table 1). Despite the enhanced sur-
vival in patients after progression from initial therapy,
neither a survival advantage nor a benefit with respect to
the response rate or time to progression was seen with the
addition of gefitinib or erlotinib to chemotherapy in any
of these trials. A retrospective subgroup analysis suggested
that the addition of erlotinib to carboplatin and paclitaxel
significantly prolonged survival only in the subgroup of
patients who had never smoked [19]. Two possible expla-
nations for the lack of benefit when TKIs are added to
chemotherapy are interactions between TKIs and chemo-
therapy and lack of patient selection for the TKI target
(EGFR) [21]. TKIs result primarily in G1 cell arrest in can-
cer cell lines with wild type EGFR, versus induction of
apoptosis in cell lines with mutant EGFR [22]. The combi-
nation of chemotherapy and TKI in some cases may cause
a G1 arrest of growth that blocks the subsequent effects of
chemotherapy. In addition, a lack of patient selection for
the target (EGFR) may also explain the lack of benefit of
TKIs [21,23]. In the phase III TRIBUTE study, for example,
that evaluated the efficacy of erlotinib plus carboplatin
and paclitaxel versus chemotherapy alone, K-RAS muta-
tions were found in 20% of the patients. These mutations
are generally associated with resistance to TKI therapy (see
section: The Role of EGFR Mutations in NSCLC). Patients
with K-RAS mutations who received erlotinib plus chem-
otherapy demonstrated worse overall survival (HR = 2.1;
95% CI, 1.1 to 3.8; P = 0.02) than patients who received
chemotherapy alone [19]. This is similar to the observa-
tion that K-RAS mutations in colon cancer do not benefit
from treatment with cetuximab [24-26].
Dose-dependent and reversible diarrhea and acne-like
rashes are the most frequently reported side effects of
TKIs. The histologic characteristics of the rash include a
neutrophilic infiltrate in perifollicular areas within the
basal layer of the skin [19,27].
Monoclonal Antibodies Against EGFR: Cetuximab, 
Panitumumab, and Matuzumab
Monoclonal antibodies that bind the extracellular
domain of EGFR prevent the receptor from interacting
with its ligand, EGF, and thus prevent intracellular signal
transduction. In addition, antibodies have the inherent
ability to recruit immune effector cells such as macro-
phages and monocytes to the tumor through the binding
of the antibody constant Fc domain to specific receptors
on these cells. This immune mechanism has been demon-
strated in xenograft models [28]. Cetuximab is a human-
mouse chimeric monoclonal antibody (IgG1 subtype)
that demonstrated activity in NSCLC. In phase 2 studies,
where cetuximab was added to platinum-based regimens,
clinical benefit was reported [29-33]. In the phase III FLEX
trial where cetuximab with cisplatin/vinorelbine was
compared with ciplatin/vinorelbine alone in 1,125
patients with EGFR-detectable advanced NSCLC, a statis-
tically significant improvement in overall survival for the
cetuximab group was reported (11.3 months vs. 10.1
months HR 0.871; 95% CI, 0.762–0.996; P = 0.0441). The
median age of patients in both study arms was 59 years,
and 94% of patients had stage IV disease [34]. Based on
this large phase III trial, the current recommendations
from the National Comprehensive Cancer Network, Inc.
(NCCN) include cetuximab/vinorelbine/cisplatin as a
first-line therapy option in patients who meet criteria for
therapy with cetuximab (i.e. NSCLC IIIB with a pleural
effusion or stage IV, EGFR expression by immunohisto-
chemistry [≥ 1 positive tumor cell], age ≥ 18, ECOG PS 0–
2, no known brain metastasis and no prior chemotherapy
or anti-EGFR therapy) [35]. Data on the role of K-RAS
mutations as predictive for benefit from cetuximab in
NSCLC is expected.
Cetuximab is relatively well tolerated. The most common
adverse events reported in a phase I trial were fever and
chills, asthenia, skin toxicity (flushing, acne-like rash, and
folliculitis), transient elevations in aminotransferase lev-
els, and nausea [36].
Panitumumab (ABX-EGF, Vectibix®), a fully human mon-
oclonal antibody (IgG2k subtype), and matuzumab
(EMD 72000), a humanized monoclonal antibody (IgG1
subtype) are in phase II and III testing. Both target EGFR
but at different epitopes. Panitumumab binds domain III
of EGFR, the same locus as cetuximab, and thus blocks all
known EGFR ligands. This results in inhibition of receptor
activation [37]. Matuzumab binds to a distinct portion of
domain III, and unlike panitumumab and cetuximab,
sterically blocks the domain rearrangement that is
required for high-affinity ligand binding and receptor
dimerization [38].
Panitumumab was well tolerated in phase I studies, where
the most common toxicity was a transient acneiform skin
rash, typically grade 1 or 2. No human antihuman anti-
bodies have been reported to date [39,40]. A randomized
phase II trial in previously untreated advanced stage IIIB
and stage IV NSCLC patients compared carboplatin (AUC
6 IV every 3 weeks) and paclitaxel (200 mg/m2 IV every 3
weeks) with or without panitumumab (2.5 mg/kg
weekly). In this trial there was no benefit appreciated with
regard to time to disease progression (4.2 vs. 5.3 months
for chemotherapy alone, P = 0.55). Also, there was no
reported benefit in response rate or median survival time.
Based on this disappointing phase II trial there has been
little enthusiasm for evaluating panitumumab in a phase
III trial [40,41]. Nevertheless, this situation requires reas-
sessment in view of the positive trial with cetuximab.Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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Table 1: Selected phase II and III clinical trials of anti-EGFR drugs in non-small cell lung cancer
Study Disease Setting Treatment 
(dose) (No. of 
patients)
ORR (CR+PR) 
(%)
mTTP (months) mPFS (months) mOS (months)
Single arm phase II 
(Perez-Soler et al.)
Metastatic 
platinum 
refractory
disease
erlotinib 
monotherapy
(150 mg/day) (57)
12.3 N.R. N.R. 8.4
Randomized
phase II, IDEAL 1 
trial 
(Fukuoka et al.)
Metastatic 
platinum 
refractory
disease
(second and third 
line of treatment)
gefitinib 
monotherapy
(250 mg/day) (103)
gefitinib 
monotherapy
(500 mg/day) (106)
18.4
19.0
(p = NS)
N.R. 2.7
2.8
(p = NS)
7.6
8.0
(p = NS)
Randomized
phase II, IDEAL 2
trial (Kris et al.)
Metastatic 
platinum and
Docetaxel 
refractory
disease (third
line of treatment)
gefitinib 
monotherapy
(250 mg/day) (102)
gefitinib 
monotherapy
(500 mg/day) (114)
12
9
(p = NS)
N.R. N.R. 7.0
6.0
(p = NS)
Randomized
phase III, BR.21 
trial (Sheperd et
al.)
Metastatic 
platinum 
refractory
disease
(second and third 
line of treatment)
erlotinib 
monotherapy
(150 mg/day) (448)
Placebo (243)
9
<1
(p < 0.0001)
N.R. 2.2
1.8
HR 0.70 
(95% CI, 0.58–
0.87)
(p < 0.001)
6.7
4.7
HR 0.61 (95%
CI, 0.51–0.74)
(p = 0.001)
Randomized
phase III, ISEL
trial 
(Thatcher et al.)
Metastatic 
platinum 
refractory disease
(second and third 
line of treatment)
gefitinib 
monotherapy
(250 mg/day) 
(1129)
Placebo (563)
8
1
(p < 0.0001)
N.R. N.R. 5.6
5.1
HR 0.89 (95%
CI, 0.77–1.02)
(p = NS)
Randomized
phase III, BETA 
tiial 
(Hainsworth et al.)
Metastatic, second 
line therapy
Erlotinib 
monotherapy
(150 mg/day) (313)
erlotinib (150 mg/
day) + 
bevacizumab (15 
mg/kg) (313)
6.2
6.2
(p = 0.006)
N.R. 1.7
3.4
HR 0.62 (95% CI 
0.52–0.75) 
(p < 0.0001)
9.2
9.3
HR 0.97 (95% CI, 
0.80–1.18) 
(p = NS)
Randomized
phase III,
INTEREST trial
(Kim et al.)
Metastatic 
platinum 
refractory
disease
(second line of
treatment)
gefitinib 
monotherapy
(250 mg/day) (733)
Docetaxel (733)
9.1
7.6
(p = NS)
N.R. 2.2
2.7
HR 1.04 
(95% CI, 0.93–
1.18)
(p = NS)
7.6
8.0
HR 1.02 (95%
CI, 0.90–1.15)
(p = NS)
Randomized
phase III,
TRIBUTE trial
(Herbst et al.)
Metastatic, first 
line treatment
carboplatin + 
paclitaxel
+ erlotinib 
(150 mg/day)
(539)
carboplatin + 
paclitaxel
+ placebo (540)
21.5
19.3
(p = NS)
5.1
4.9
(p = NS)
N.R. 10.6
10.5
(p = NS)Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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Matuzumab, another monoclonal antibody that targets
EGFR is approximately 90% humanized and 10% murine.
In phase I testing it was well tolerated with grade 1 or 2
skin toxicity reported in two thirds of the patients [42,43].
It has a half-life of approximately 10 days permitting effec-
tive administration once every two or three weeks [44].
Matuzumab is currently undergoing phase II evaluation in
NSCLC [45].
Predictors of Response-The Role of EGFR Mutations in 
NSCLC
Predicting which patients are most likely to benefit from
EGFR targeted therapy remains a challenge. The studies of
erlotinib and gefitinib identified a population that is
more likely to respond to anti-EGFR therapy, i.e. never-
smokers, of Asian heritage, female sex, and a tumor with
adenocarcinoma histology. The presence of cutaneous
side effects has also been correlated with response rates
[46].
At the molecular level, most patients with partial or com-
plete responses to gefitinib and erlotinib harbored specific
mutations in the gene that encodes EGFR, located on
chromosome 7p12 [47]. Exon 19 mutations, character-
ized by in-frame deletions of amino-acids 747–750,
account for 45% of mutations, exon 21 mutations, result-
ing in L858R substitutions, account for 40–45% of muta-
tions, and the remaining 10% of mutations involve exon
18 and 20 [48-51]. These mutations have been shown, in
vitro, to increase the kinase activity of EGFR, leading to
the hyperactivation of downstream pro-survival path-
ways, and consequently confer oncogenic properties on
EGFR [52-54]. These mutants are also more sensitive to
inhibition by gefitinib and erlotinib than are the wild-
type receptors.
Overall, the incidence of EGFR mutations in NSCLC
among clinical responders to gefitinb or erlotinib is 77%,
compared with 7% in NSCLC cases that do not have a CR
or PR [55-57]. In studies with unselected NSCLC patients,
EGFR mutations are found in approximately 10% of cases
in North America and Western Europe, and approxi-
mately 30–50% of cases from East Asia [49,50]. These
mutations may be limited to non-small-cell lung cancer,
Randomized
phase III,
TALENT trial
(Gatzmeier et
al.)
Metastatic, first 
line
treatment
cisplatin + 
gemcitabine +
erlotinib 
(150 mg/day)
(533)
cisplatin + 
gemcitabine +
placebo (536)
31.5
29.9
(p = NS)
5.1
4.9
(p = NS)
N.R. 10.0
10.3
(p = NS)
Randomized
phase III,
INTACT-1 trial 
(Giaccone et al.)
Metastatic, first 
line
treatment
cisplatin + 
gemcitabine +
gefitinib 
(250 mg/day)
(365)
cisplatin + 
gemcitabine +
gefitinib 
(500 mg/day)
(365)
cisplatin + 
gemcitabine +
placebo (363)
51.2
50.3
47.2
(p = NS)
N.R. 5.8
5.5
6.0
(p = NS)
9.9
9.9
10.9
(p = NS)
Randomized
phase III,
INTACT-2 trial
(Herbst et al.)
Metastatic, first 
line
treatment
carboplatin + 
paclitaxel
+ gefitinib 
(250 mg/day)
(345)
cisplatin + 
paclitaxel +
gefitinib 
(500 mg/day)
(347)
cisplatin + 
paclitaxel +
placebo (345)
30.4
30
28.7
(p = NS)
N.R. 5.3
4.6
5.0
(p = NS)
9.8
8.7
9.9
(p = NS)
NSCLC, non-small-cell lung cancer; ORR, overall response rate; CR, Complete response; PR, partial response; mPFS, median progression free 
survival; m TTP, median time to progression; mOS: median overall survival; HR, hazard ratio; CI, confidence interval; N.R.: not reported.
Table 1: Selected phase II and III clinical trials of anti-EGFR drugs in non-small cell lung cancer (Continued)Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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as they are rarely identified in other human cancers. The
presence of EGFR kinase mutations seem to be highly cor-
related with clinical characteristics, i.e. female sex, never
smokers, Asian descent, adenocarcinoma histology,
whereas, in patients with smoking-associated cancers,
EGFR gene amplification, as measured by qPCR may be
an oncogenic driving force [58].
Increased EGFR gene copy number as determined by fluo-
rescent in situ hybridization (FISH) and EGFR protein
overexpression measured by immunohistochemistry
(IHC) are correlated with improved response and survival
to TKI therapy [59,60]. In the BR.21 trial, for example, the
positive treatment effect of erlotinib was confined to the
EGFR FISH positive patients (gene amplification and/or
high polysomy) both in terms of response rate (20% for
FISH positive and 2% for FISH negative) and survival
(HR, 0.44 for FISH positive and HR, 0.85 for FISH nega-
tive) [61]. However, in a multivariable analysis no molec-
ular markers were predictive for survival.
In a cohort of NSCLC patients from Italy treated with
gefitinib, EGFR protein overexpression (IHC positive) was
demonstrated in 59% of tumors, and was associated with
increased response (21% vs. 5%; P = 0.03) and survival
(11.5 vs. 5 months; P = 0.01), but not with specific clinical
characteristics. The majority of mutation positive cases
that responded to treatment were also FISH positive; how-
ever, both IHC positive status and EGFR mutations were
associated with FISH positivity [59,62].
In the ISEL trial evaluating gefitinib in NSCLC, the sub-
group of patients with EGFR mutations had a higher
response rate to TKI therapy. Twelve percent of patients
were found to have EGFR mutations, and they had a
higher response rate (37.5%) with gefitinib treatment
than mutation-negative patients (2.6%, P value not
reported). FISH positive status was observed in 30.8% of
patients and was associated with a nonsignificant trend
toward improved survival with gefitinib treatment (HR =
0.61; 95% CI, 0.36 to 1.04) [63].
The INVITE trial, that compared gefitinb with vinorelbine
in chemotherapy naïve, unselected elderly patients with
advanced NSCLC, reported no statistical difference in out-
come, with improved tolerability for gefitinib. One unex-
pected finding was noted in the EGFR-FISH analysis:
individuals who were FISH positive appeared to benefit to
a greater extent from vinorelbine than from gefitinib. This
finding was in contrast with previous trials that showed a
survival improvement for patients who were EGFR FISH-
positive and who received an EGFR-TKI. A sampling error
due to incomplete EGFR FISH testing may have contrib-
uted to these findings. For example, the authors reported
that this analysis was limited in that mutation analysis
was performed in a "limited number of instances,"
because ethics committee approval was obtained in only
a few centers [10].
Preliminary results from the IPASS study were presented
at the European Society for Medical Oncology in Septem-
ber of 2008. This phase III trial evaluated gefitinib vs. car-
boplatin/paclitaxel in 1217 Asian patients with advanced
NSCLC who had not received prior systemic therapy and
who had never smoked or were light former smokers.
Based on clinical factors the population was enriched for
EGFR mutations. Indeed, among the evaluable patients,
the overall EGFR mutation positive rate was 59.7%. The
primary endpoint was progression free survival (PFS), and
it showed a significant difference favoring gefitinib (HR =
0.68; 95% CI, 0.58 to 0.81; P < 0.0001). Among patients
with EGFR mutations the response rate was significantly
greater for those treated with gefitinib (odds ratio [OR]
2.75; 95% CI, 1.65 to 4.6, P = 0.001) while in patients
without an EGFR mutation response rate was greater with
chemotherapy (OR 0.04; 95% CI, 0.01 to 0.27; P =
0.0013). Quality of life analysis favored gefitinib as well
(P = 0.0148). Median overall survival appeared similar
between the two groups although definitive results were
not presented [64]. An update presented at the Chicago
Multidisciplinary Symposium in Thoracic Oncology in
November 2008 verified the earlier findings, and reported
improved quality of life scores for patients receiving gefit-
inib compared with chemotherapy. Likewise, gefitinib
had a more favorable tolerability profile than carboplatin/
paclitaxel [65]. This trial supports the observation that
patients with EGFR mutations have a better prognosis and
may benefit from both TKI therapy and from cytotoxic
chemotherapy.
The INTEREST trial was a randomized phase III trial that
compared gefitinib versus docetaxel in previously treated
NSCLC. In this trial, the patients were randomly assigned
after dynamic balancing with respect to histology (adeno-
carcinoma vs. other). The authors reported that specific
clinical factors (never-smokers, Asian origin, female sex,
and adenocarcinoma histology) were associated with a
longer survival in both the gefitinib and docetaxel groups
[66]. This was unexpected since previous trials suggested
that chemotherapy produces similar survival in all
patients.
Another trial evaluated EGFR mRNA expression and gene
dosage, both assayed by quantitative PCR (qPCR) in
tumor samples from patients with gefitinib-treated
NSCLC. Unlike FISH that allows for quantification of
gene copy number in individual tumor cells, qPCR tech-
niques assess gene copy number or mRNA levels in a pool
of cells. Often tumor microdissection is necessary to
ensure that a high percentage of tumor cells are present inJournal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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the analyzed sample. Also, deletions or amplifications of
genetic material within tumor cells may limit the accuracy
of qPCR [67]. In this trial, EGFR mRNA expression was
predictive of response to gefitinib therapy and for PFS
after treatment, while EGFR gene dosage was not associ-
ated with a response to therapy or outcome. Also, high
EGFR mRNA expression was correlated with increased
EGFR gene copy number as evaluated by FISH [68]. These
findings support the use of qPCR to determine EGFR
mRNA expression in NSCLC.
One of the downstream messengers of EGFR that trans-
duces the EGFR activation signal within the cell is K-RAS.
K-RAS gene mutations on codons 12, 13, and 61 result in
constitutive activation of the RAS protein, which may
render tumor cells independent of EGFR signaling and
also resistant to anti EGFR therapy [69]. Significantly, K-
RAS mutations are found almost exclusively in smoking-
associated NSCLC with wild-type EGFR [70-72].
In the previously described phase III TRIBUTE trial that
compared chemotherapy with carboplatin/paclitaxel
alone to the same regimen with the addition of erlotinib,
patients with K-RAS mutations in the erlotinib group had
a worse survival than those who received chemotherapy
alone [19,73]. A similar retrospective analysis was per-
formed in patients on the BR.21 trial. In this trial, 10% of
98 K-RAS wild-type patients assessable for response had
confirmed response to erlotinib, whereas only one of the
20 K-RAS mutant patients responded (this patient also
had EGFR amplification) [74]. Genetic analysis of both
trials supports the theory that NSCLC patients with K-RAS
mutations are unlikely to respond to anti EGFR therapy.
Another subgroup analysis from the TRIBUTE study eval-
uated EGFR gene copy number using FISH found that the
EGFR gene copy number did not predict an overall sur-
vival benefit. However, among EGFR FISH positive
patients the time to progression was longer in patients
who received erlotinib and continued to receive it after
completing first-line therapy (HR = 0.59; 95% CI, 0.35 to
0.99; P = 0.0403) [75]. This lends additional support to
the lack of benefit of combining chemotherapy with TKIs,
while suggesting the possible benefit of TKI therapy as
part of a maintenance regimen. The point where the TTP
curves diverged was after 6 months, when erlotinib was
continued alone. The ATLAS trial of maintenance bevaci-
zumab +/- erlotinib may help clarify the utility of TKIs in
maintenance therapy for NSCLC. The trial is now closed,
and results are expected in the first half of 2009 [76,77].
Acquired Resistance to EGFR-Targeted Therapy
In approximately 50% of patients who initially respond to
TKIs but later relapse, the T790M mutation in exon 20 of
the EGFR gene occurs as a single secondary event [78,79].
It has been proposed that this second mutation may
weaken the interaction of inhibitors with the target kinase
[80]. Other possible routes for acquired resistance to TKIs
include: metalloproteinase 17 (ADAM17) mediated auto-
crine activation of ERBB2 and ERBB3, amplification of
EGFR, hyperactivation of downstream signaling compo-
nents that circumvent EGFR inhibition, cellular changes
that alter the bioavailability of the inhibiting drugs, and
drug-resistance through ATP-binding cassette GE
(ABCG2) transporter which actively pumps the cytotoxic
agent out of the tumor cells [48,81].
Second Generation Small Molecule TKIs
Novel agents have been designed to overcome the steric
interference to drug binding that is conferred by the
T790M and other mutations. One group of drugs that
bind irreversibly to the active site of EGFR was shown in
vivo to overcome the resistance to EGFR RTKs. These have
been termed second generation TKIs. A summary of the
early studies involving these agents is included in Table
2[82-87]. One example among the second generation
TKIs is XL647. This is a reversible inhibitor of EGFR,
HER2, and vascular epidermal growth factor receptor
(VEGF). Preclinical evaluation demonstrates that XL647
can inhibit cell lines bearing mutated forms of EGFR that
have been associated with acquired resistance [82,84].
Preliminary data from phase II trial showed a response
rate of 29% (N = 34). In patients with tissue available,
EGFR mutation analysis was performed. Although 6 of the
10 patients with partial response had EGFR mutations, 3
patients had wild-type EGFR. Of the seven patients with
classic EGFR mutations, six had a partial response, and
one had prolonged stable disease [85].
The most common therapy related adverse events for
XL647 were grade 1 or 2 diarrhea, rash, fatigue and nau-
sea. Phase II data revealed that nearly 50% of patients
experienced a prolongation in the QTc. The vast majority
of these EKG changes were grade 1 or 2, although 6% of
patients were found to have grade 3 toxicity [85].
Targeting HER2 in NSCLC
HER2 is a member of the EGF (ERBB) family of tyrosine
kinase receptors to which EGFR also belongs. HER2 is dys-
regulated in many cancers, where it is commonly overex-
pressed by amplification. When HER2 is overexpressed, as
in breast and ovarian cancers, it is associated with a poor
prognosis [88,89].
Signal transduction by HER2 is distinct from other mem-
bers of the EGF family of receptors. For example, the bind-
ing of EGFR to it's ligand induces the formation of homo
and hetero-dimers among the EGFR related receptors.
Dimerization results in activation of the intrinsic kinase
domain within the cell. This contrasts with HER2 activa-Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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Table 2: Targeted therapeutic agents in NSCLC
Class Agent Target Company Stage of development in 
NSCLC
First Generation TKI
Gefitinib EGFR (reversable) AstraZeneca Approved for a restricted group 
of patients
Erlotinib EGFR
(reversable)
OSI, Genentec and Roche Approved
Second Generation TKI
EKB-569 EGFR (irreversible) Wyeth Phase II
CL-387,785 EGFR
(irreversible)
Wyeth Preclinical
Multi-Targeted TKI
HKI-272 EGFR, HER2
(irreversible)
Wyeth Phase I/II
Canertinib EGFR, HER2, HER4
(irreversible)
Pfizer Inc. Phsae II
BIBW 2992 EGFR, HER2
(irreversible)
Boehringer Ingelheim Phase I/II
HKI-357 EGFR, HER2
(irreversible)
Wyeth Preclinical
Vandetanib, ZD-6474 EGFR, HER2, FLT1, KDR
(reversible)
AtraZeneca Phase III
XL647 EGFR, HER2, KDR, EPHB4
(reversible)
Exelexis Phase II
HER2 Heterodimerization
BMS-599626 EGFR, HER2 Bristol-Myers Squibb Phase I
Macrolide Derivatives
RAD001 mTOR Novartis Pharma AG Phase II
CCI-779 mTOR Wyeth Phase II
AP23573 mTOR Ariad Pharmaceuticals Phase I
Monoclonal Antibodies
Cetuximab EGFR
(chimeric mAB)
ImClone/Merk KGaA Bristol-Myers 
Squibb
Approved
Matuzumab EGFR
(humanized mAb)
Merck KgaA Phase IIJournal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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tion that (unlike EGFR, HER3, and HER4) does not have
an extracellular ligand-binding site (receptor). It dimer-
izes with other members of the EGF family (heterodimer)
or with itself (homodimer). The strongest and the most
potent heterodimer formed is EGFR/HER2 [90].
Recent studies have reported that mutations in the tyro-
sine kinase domain of HER2 are occasionally detected in
lung cancers [91]. One retrospective trial, for example,
analyzed tumors from 116 patients in relation to smoking
status. EGFR mutations were detected in 20 of 116 (17%)
tumors, whereas five (4.3%) tumors contained HER2
mutations. No tumor contained both mutations. Of
tumors with EGFR or HER2 mutation, 72% were adeno-
carcinomas, 68% were from never smokers, and 32% were
from former smokers. EGFR but not HER2 mutations
were mutually exclusive with KRAS mutation [89].
This small study highlights the diversity of genetic aberra-
tions identified in NSCLC. Some of the second generation
TKIs that target HER2 along with EGFR may show activity
in patients who initially respond to TKIs but later develop
resistance, if that resistance is mediated by mutations in
HER2.
Trastuzumab, a monoclonal antibody directed against
HER2, has been evaluated in NSCLC. It had no significant
clinical activity when given either as a single agent or in
combination with platinum based chemotherapy even in
NSCLC with over expression of HER2 [92-96]. A pan HER
inhibitor, PF-00299804, that binds irreversibly to EGFR,
HER2, and HER4, in a phase I trial induced 2 PRs among
44 patients with advanced NSCLC after failure of prior
treatment with reversible EGFR inhibitors [97].
mTOR Inhibitors, Rapamycin Derivatives: CCI-779 
(Temsirolimus), RAD001 (Everolimus)
Mammalian target of rapamycin (mTOR) kinase is an
important mediator of tumor cell growth and prolifera-
tion. It is activated in >50% of lung carcinomas [98]. It is
located downstream, along the PI3K-AKT pathway where
it serves as a central sensor for nutrient/energy availability
[6,99]. In the presence of stimulation at the EGFR receptor
in combination with sufficient nutrients and energy, the
mTOR pathway is activated, and cell growth is initiated.
Several agents that inhibit mTOR are currently in clinical
trials. Preliminary results from the first 50 patients
enrolled in a phase II trial of CCI-779 who were previ-
Panitumumab EGFR
(humanized mAb)
Abgenix Phase II/III,
Trastuzumab HER2
(humanized mAb)
Genentech/Roche Approved
Bevacizumab VEGF-A Genentech Approved
VEGF Inhibitors
Sorafenib VEGFR2, FLT3, PDGFR, fibroblast 
growth factor receptor-1
Bayer HealthCare Pharmaceuticals 
and Onyx Pharmaceuticals
Phase III
Sunitinib c-kit, VEGFR1-3, PDGFRa, PDGFRb, 
Flt-3, CSF-1R, ret
Pfizer Inc. Phase II/III
Axitinib AG013736 VEGF 1-3, PDGFR, cKIT Pfizer Inc. phase II
Regeneron VEGF-Trap Phase I
Non VEGF Angiogenesis inhibitors
Celecoxib COX-2 Pfizer Inc. Phase II
Proteasome Inhibitors
Bortezomib Inhibits 26S proteasome Millennium Pharmaceuticals, Inc. Phase II
Retinoic Acid Receptor
Bexarotene Retinoid × receptor Eisai Inc. Phase III
Table 2: Targeted therapeutic agents in NSCLC (Continued)Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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ously untreated for NSCLC reported 4 patients with a par-
tial response (PR rate of 8%), and 15 patients with stable
disease (SD rate of 30%). The median PFS time was 2.3
months and the median OS time was 6.6 months
(100,101). The most common grade 3 or 4 toxicities for
CCI-779 were dyspnea (12%), fatigue (10%), hyperglyc-
emia (8%), hypoxia (8%), nausea (8%), and rash (6%).
Another mTOR inhibitor, RAD001 was evaluated in a
phase II of patients with an ECOG performance status of
two or higher who failed ≤ 2 cycles of platinum-based
therapy (arm 1) vs. those who failed ≤ 2 cycles of plati-
num-based therapy as well as an EGFR antagonist. From
74 evaluable patients, the median PFS was 11.3 weeks in
arm 1 and 9.7 weeks in arm 2. The most frequent adverse
events were stomatitis/mucositis, cough, dyspnea, rash,
fatigue, anorexia, nausea, anemia, epistaxis and diarrhea.
The molecular marker portion of the study is still ongoing
[102].
An exciting phase II trial is currently underway combining
mTOR and EGFR inhibition in NSCLC. There is some pre-
clinical data suggesting synergy between gefitinib and
everolimus [103]. This regimen was tolerable for patients
in phase I trials, although the incidence of diarrhea, rash
and mucosal ulcerations were high [104-106].
Targeting Angiogenesis and VEGF
Like normal tissue, tumors require access to the circula-
tion in order to grow and survive. The process of develop-
ing vasculature through angiogenesis is complex, and
offers multiple diverse targets for anti-cancer therapeutics.
Vascular endothelial growth factor is the dominant
growth factor controlling angiogenesis. VEGF comprises a
family of growth factors including: placental growth fac-
tor, VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E (orf
virus VEGF) (Figure 4).
VEGF-A is the major mediator of tumor angiogenesis, and
is the target of the monoclonal antibody bevacizumab
[107-109]. VEGF ligands mediate angiogenesis via several
receptors including VEGFR-1 (Flt-1) and VEGFR-2 (KDR,
Flk-1), and lymphangiogenesis via VEGFR-3 (Flt-4) [109-
111]. Normal endothelial cells express VEGFR-2, and nor-
mal vascular tissues express either VEGFR-1 or VEGFR-3.
This contrasts with tumors that have been shown to
express several different VEGF ligands simultaneously
[109,112]. VEGF receptors in normal tissues are involved
in a range of cellular pathways that vary with the stage of
development of the organism as well as with the physio-
logic and pathologic conditions. Both VEGFR-1 and
VEGFR-2 can bind the VEGF-A ligand promoting angio-
genesis. VEGFR-1 is critical for physiologic and develop-
mental angiogenesis [113,114]. VEGFR-2 mediates
microvascular permeability, endothelial cell proliferation,
invasion, migration, and survival. Signaling by VEGF-2
may be positively or negatively influenced by co-expres-
sion and activation of VEGFR-1.
In growing tumors VEGFR-1 and VEGFR-2 have been
shown to be a potent positive regulator of angiogenesis
[113]. VEGFRs have been identified on the surface of
tumor cells in a range of malignancies including NSCLC
[114]. It has been proposed that tumor cells abnormally
expressing VEGFRs that also secrete VEGF induce an auto-
crine loop promoting tumor angiogenesis [115]. Support
of this hypothesis is demonstrated by activation of MAPK
pathway in tumor cells after VEGFR-1 activation by VEGF-
A or VEGF-B [116,117].
It logically follows that targeting VEGF and VEGFR should
destroy the tumor vasculature and starve the tumor of oxy-
gen and nutrients. In fact, VEGF blockade as monotherapy
has been clearly shown to have a direct and rapid anti-vas-
cular effect in both animal and human tumors [118].
However, it has also been proposed that certain antiang-
iogenic agents can also transiently "normalize" the abnor-
mal structure and function of tumor vasculature to make
VEGF signaling pathways Figure 4
VEGF signaling pathways. Binding specificity of various 
vascular endothelial growth factor (VEGF) family members 
and their receptors. The VEGF family consists of seven lig-
ands derived from distinct genes (VEGF-A, -B, -C, -D, and -E, 
placenta growth factor [PIGF] -1 and -2). VEGF family mem-
bers have specific binding affinities to VEGF receptor 
(VEGFR) -1, VEGFR-2 and BEGFR-3 tyrosine kinase recep-
tors as shown. In addition, neuropilin (NRP)-1 and NRP-2 are 
co-receptors for specific isoforms of VEGF family members 
and increase binding affinity of these ligands to their respec-
tive receptors. Used with permission from: Hicklin DJ, Ellis 
LM. Role of the vascular endothelial growth factor pathway 
in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 
1011–27.Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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it more efficient for oxygen and drug delivery [119,120].
This supports the use of angiogenesis medication in com-
bination with chemotherapeutic agents.
Angiogenesis Inhibitors: Bevacizumab
Bevacizumab is a humanized monoclonal antibody
directed against VEGF that recognizes all isoforms of
VEGF-A. It has a long half life of 17 to 21 days after IV
infusion [121]. A pivotal phase III trial in NSCLC, ECOG
4599, showed that adding bevacizumab to paclitaxel plus
carboplatin resulted in a survival advantage compared
with chemotherapy alone in patients with recurrent or
advanced NSCLC. The median survival was 12.3 months
in the chemotherapy plus bevacizumab group compared
with 10.3 months in the chemotherapy alone group (haz-
ard ratio for death, 0.79; p = 0.003) [122]. In this trial
patients with squamous-cell tumors, brain metastasis,
clinically significant hemoptysis, or inadequate organ
function or performance status (ECOG performance sta-
tus, >1) were excluded.
The addition of bevacizumab resulted in increased rates of
hypertension, proteinuria, bleeding, neutropenia, febrile
neutropenia, thrombicytopenai, hyponatremia, rash, and
headache when compared with the paclitaxel/carboplatin
alone group (P < 0.05). Of significant note was the increased
rate of death from pulmonary hemorrhage, cerebrovascular
events, and gastrointestinal hemorrhage [122].
Another phase III trial, AVAIL (BO17704), evaluated the
addition of bevacizumab to cisplatin/gemcitabine, a regi-
men that is commonly used in regions outside of the US.
This randomized, placebo-controlled phase III study com-
pared two doses of bevacizumab plus cisplatin/gemcitab-
ine to cisplatin/gemcitabine plus placebo in 1,043
patients. The eligibility criteria included: previously
untreated advanced or recurrent non-squamous NSCLC,
ECOG PS 0–1, and no brain metastases. PFS was signifi-
cantly prolonged as analyzed both in a primary analysis
(without censoring for non-protocol anti-neoplastic ther-
apy [NPT] prior to progression) and in a pre-specified
analysis with censoring for NPT. The response rate (RR)
and response duration were also increased. An initial
company press release indicated that the difference in sur-
vival was not statistically significant [123]. The authors
concluded that bevacizumab significantly improved PFS
and RR, consistent with the results of the earlier phase III
trial E4599 [124]. With longer follow-up, the preliminary
findings were supported. The risk of progression or death
was reduced by 25% with bevacizumab 7.5 mg/kg and
15% with bevacizumab 15 mg/kg vs. placebo (P = 0.003
and 0.046, respectively) [125].
Angiogensis Inhibitors: AVE0005 (VEGF Trap)
VEGF Trap is a recombinant fusion molecule with a high-
affinity for binding to all isoforms of VEGF and to placen-
tal growth factor. It has been postulated that the improved
affinity may allow more efficient depletion of tissue and
plasma VEGF [126]. Initial phase II results in patients with
platinum and erlotinib resistant adenocarcinoma of the
lung revealed two PRs (6%) and 63% with SD among the
first 33 evaluable patients. Grade 3–4 treatment related
adverse events included dyspnea (15%), hypertension/
non-cardiac chest pain (9%), fatigue (6%), and anxiety,
epistaxis, nausea, bone pain, proteinuris, febrile neutro-
penia, pneumonia, pulmonary emvolism and renal pain
(each 3%). No grade 3 or greater hemoptysis was reported
[127,128].
Angiogenesis Inhibitors: COX-2 Inhibitors
Cyclooxygenase-2 (COX-2) is an enzyme in the arachi-
donic acid cascade that is unregulated and overexpressed
in many tumors, including lung cancer. It has been pro-
posed that increased COX-2 enzyme may create a surplus
of prostaglandin E2 (PGE2). PGE2 then promotes tumor
growth and invasion through the stimulation of VEGF
and the upregulation of bcl-2 and various matrix metallo-
proteinases [129]. In clinical trials COX-2 inhibition with
celecoxib has not been shown to be effective when com-
bined with irinotecan/docetaxel or irinotecan/gemcitab-
ine [130].
Multitargeted Agents: Sunitinib, Sorafenib, Vandetanib 
and Axitinib
Sunitinib malate is an oral, multitargeted tyrosine kinase
inhibitor with antiangiogenic and antitumor activities. It
inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha,
PDGFR-beta, KIT, RET and FLT3. In NSCLC it was evalu-
ated in a Phase II clinical trial where 63 patients with
advanced NSCLC who failed platinum-based chemother-
apy were treated with sunitinib (50 mg/day) for 4 weeks
followed by 2 weeks of no treatment for each 6 week cycle.
Seven patients achieved a PR, and 18 patients had stable
disease. The median progression-free survival was 12.0
weeks (95% CI, 10–16.1 weeks), and the median overall
survival was 23.4 weeks (95% CI, 17–28.3 weeks). The 1-
year survival rate was 20.2% [131].
The toxicities reported in this trial from sunitinib were
predominantly grade 1 to 2, and did not interfere with
scheduled treatment. Grade 3 or 4 adverse events included
fatigue/asthenia (29%), pain/myalgia (17%), dyspnea
(11%), and nausea/vomiting (10%). Three hemorrhage-
related deaths were reported among the 63 total partici-
pants. Two of the hemorrhage-related deaths were attrib-
uted to sunitinib, and both resulted in pulmonary
hemorrhage [131].
A second phase II trial with the same inclusion criteria was
designed to evaluate a continuous dosing schedule for
suntinib. In this trial sunitinib was given 37.5 mg/day
orally. 47 patients were accrued and evaluated with aJournal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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median duration of therapy of 92 days (range 12–336
days). A response rate of 2.1% (95% CI, 0.1 to 11.1) with
a 19.1% rate of disease stabilization was reported. The
median time to progression was 12.3 weeks (95% CI, 8.9
to 16 weeks), and the median survival time was 38.1
weeks (95% CI, 31.1 to unavailable) [132]. Although the
trials cannot be directly compared since they were per-
formed in a sequential fashion, both dosing schedules
showed activity in NSCLC.
There are several ongoing clinical studies in NSCLC incor-
porating sunitinib. One is Cancer and Leukemia Group B
(CALGB) 30607 evaluating the use of maintenance
sunitinib compared with placebo in patients with
advanced stage IIIB or stage IV NCSLC who have non-pro-
gressing disease after four cycles of platinum-based chem-
otherapy. The primary end point is progression-free
survival [133]. There is a phase II and a phase III trial
underway evaluating the combination of erlotinib with or
without sunitinib. In addition, the combinations of
sunitinib with other chemotherapeutic agents including
docetaxel, platinum, gemcitabine, and pemetrexed are
currently underway [133]. A phase I trial presented at the
2007 ASCO annual meeting incorporating sunitinib with
docetaxel in patients with advanced solid tumors includ-
ing 13 patients with NSCLC, showed encouraging results
[134].
Sorafenib is an oral multi-kinase inhibitor that targets
RAF, VEGFR-2, and VEGFR-3. In a phase II trial that eval-
uated 54 patients with relapsed or refractory NSCLC
approximately 60% of patient achieved disease stabiliza-
tion [135]. When sorafenib was combined with carbopla-
tin and paclitaxel in 15 patients with advanced,
progressive NSCLC the disease control rate (objective
response plus stable disease) was 79%. The duration of
response was 25 weeks, and the median progression free
survival was 34 weeks [136].
One small phase II trial employed sorafenib alone in 25
patients with chemo-naïve stage IIIB (wet) or stage IV
patients. Three patients had a PR and 7 patients had stable
disease. The PFS and MS was 2.9 and 8.8 months respec-
tively [137].
The phase III ESCAPE trial that evaluated sorafenib with
carboplatin/paclitaxel in patients with NSCLC was
stopped early when a planned interim analysis concluded
that the study would not meet its primary endpoint of
improved overall survival. A higher mortality was
observed in the subset of patients with squamous cell car-
cinoma who received sorafenib and chemotherapy com-
pared with those that only received chemotherapy.
Another phase III trial with sarafenib, NexUS, is accruing
patients [138].
Vandetanib (ZD6474) is a once-daily inhibitor of VEGFR-
2 and RET kinase inhibitor. In a phase II trial of patients
with locally advanced or metastatic NSCLC who failed
first-line platinum-based chemotherapy, vandetanib plus
docetaxel demonstrated a significant prolongation of PFS
compared with docetaxel, 18.7 vs. 12 weeks (HR = 0.64;
one sided P = 0.037) [139]. Based on these encouraging
findings, phase III studies of vandetanib are currently
underway.
Axitinib (AG-013736) is a small molecule inhibitor that
targets VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-beta, and
cKIT. It was evaluated in a phase II trial of 32 patients with
advanced NSCLC. 72% had received prior chemotherapy.
In this trial 3 patients responded. The median duration of
response was 9.4 months. The median survival was 12.8
months (95% CI, 9.9 to undefined), and progression-free
survival was 5.8 months (95% CI, 3.8 to 10.2 months)
[140].
Targeting the Proteasome: bortezomib
Bortezomib is a proteasome inhibitor that disrupts the
ubiquitin-proteasome pathway leading to apoptosis. In a
phase II trial of bortezomib alone and in combination
with docetaxel in 155 previously treated patients with
advanced non-small-cell lung cancer the one-year overall
survival was modestly improved in the combined therapy
arm, 39% vs. 33% [141]. The most common adverse
effects of bortezomib include peripheral neuropathy,
transient thrombocytopenia, and gastrointestinal disor-
ders (nausea, diarrhea, and constipation).
A Southwest Oncology Group phase II study (S0339)
evaluated 114 patients with chemotherapy naïve wet stage
IIIB and stage IV disease. Patients received gemcitabine/
carboplatin with bortezomib. Responses were seen in
20% of patients and 45% had stable disease. The overall
disease control rate was 66%. PFS and median overall sur-
vival were 5 and 11 months, respectively [142]. Based on
this trial, a phase III trial is underway [143].
Targeting the Retinoic Acid Receptor: Bexarotene
Analogues of vitamin A, retinoids, are required for normal
growth and differentiation of human bronchial epithe-
lium. When certain retinoid receptors in the cell nucleus
such as RAR-beta (retinoic acid receptors) and RXRs
(retinoid × receptors) are inactivated, tumors in the lungs
may develop [144,145]. In this way, retinoic acid recep-
tors act like tumor suppressors. Bexarotene is a selective
retinoid × receptor (RXR) modulator that binds RXR
alpha, beta, and gamma. In two phase III trials of bexaro-
tene with either cisplatin/vinorelbine (SPIRIT I) or carbo-
platin/paclitaxel (SPIRIT II) the addition of the selective
retinoic acid receptor inhibitor to chemotherapy did not
improve survival. However, it was reported in both stud-Journal of Hematology & Oncology 2009, 2:2 http://www.jhoonline.org/content/2/1/2
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ies that the subset of patients who developed hypertriglyc-
eridemia had a significant improvement in median
survival compared with controls (12.4 vs. 9.2 months log-
rank, P = 0.014; SPIRIT II) [146,147]. The benefit is most
pronounced when the hypertriglyceridemia is high-grade
and develops rapidly, in patients with the following char-
acteristics: men, stage IV disease, smokers, and those with
≥ 5% weight loss in previous 6 months [147].
Summary and conclusion
The search for innovative therapeutic agents in NSCLC
that are more effective and have fewer side effects than
older chemotherapeutic drugs has spurred the develop-
ment of more than 500 novel therapies. In the process of
identifying targets for therapy, our understanding of the
molecular pathways involved in malignancy has also
increased. Several novel agents including bevacizumab,
erlotinib, and cetuximab have proven that these agents
can prolong the lives of patients with advanced NSCLC.
Understanding mechanisms of tumor cell growth and sur-
vival has translated into clinical trials of drugs that have
changed the treatment landscape. The most recent NCCN
guidelines now reflect these advances. First-line therapy
for patients with metastatic disease or recurrent NSCLC
and good performance status include four treatment
options: chemotherapy alone, bevacizumab with chemo-
therapy, cisplatin with pemetrexed, or cetuximab with
vinorelbine and cisplatin.
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